Uses of Efexor Xr 37.5mg

Efexor XR with the main ingredient Venlafaxin is used to treat depressive disorders, limit spontaneous depression and social anxiety disorders. So, what precautions should be taken when using Efexor Xr?

Efexor Xr 37.5mg is indicated for use in the treatment of the following cases:
Major depressive disorder Prophylaxis of recurrent and recurrent depression General anxiety disorder or social anxiety disorder Panic disorder.

Efexor Xr is an extended-release capsule that should be taken with food. Patients should take the capsule whole with water and should take it at the same time each day. Alternatively, the medication can be administered by carefully opening the capsule and placing the entire amount in a spoonful of apple sauce. Then swallow this mixture whole and drink another glass of water to make sure all the microparticles have entered the body.
Dosage of the drug will depend on different diseases such as:
2.1. Major depressive disorder Venlafaxine extended-release capsules are recommended for use at a starting dose of 75 mg orally once daily. In cases where the patient does not respond to this initial dose, this may be increased to a maximum of 225 mg/day for moderate depression. Several studies have shown that patients with severe depression respond to a dose of 350 mg/day.
2.2. Generalized Anxiety Disorder As with major depressive disorder, the recommended starting dose of Venlafaxin extended-release capsules is 75 mg once daily. If there is no response, it can be increased to 225 mg/day and the patient should be monitored and evaluated throughout the treatment period.
2.3. Social Anxiety Disorder The recommended starting dose of Venlafaxin extended-release capsules in the treatment of social anxiety disorder is 75 mg once daily. To date, there is no evidence that increasing the dose increases the effectiveness of treatment.
2.4. Use in Renal Impairment The total dose of Venlafaxine should be reduced by 25% to 50% in patients with renal impairment with a glomerular filtration rate (GFR) between 10 and 70 mL/min. In the case of patients undergoing hemodialysis, the total daily dose should be reduced by 50%.
Due to the large variability in clearance from each patient, individual dosing is required.
2.5. Use in patients with hepatic impairment In patients with mild to moderate hepatic impairment, a 50% total daily dose of Venlafaxine should be reduced. In other cases, it may be necessary to reduce the dose of Venlafaxin by more than 50%.
2.6. How to properly discontinue Venlafaxine Dosage should be tapered whenever Venlafaxine treatment is discontinued. Through clinical trials with Venlafexin extended release, dose reduction order was achieved by reducing 75 mg/day for one week and the length of time needed was dependent on the specific disease, duration of treatment and individual patient response to treatment.
The above dosage is for reference only. Depending on the type of disease and the patient's ability to respond, the doctor will give the appropriate dose.

The drug has some contraindications for users in some of the following cases:
Patients with a history of hypersensitivity to Venlafaxin or any of its ingredients. Venlafaxine should not be used at the same time as monoamine oxidase inhibitors (MAOIs). When necessary, Venlafaxin should be used only after stopping treatment with an MAOI for at least 14 days Some patients need to be cautious when using it:
Patients with suicidal thoughts or worsening of the disease All All Patients treated with Venlafaxin should be closely monitored by family and those around them, especially when suicidal thoughts or worsening are observed. Those around need to be reminded of the possibility of some strange signs such as agitation, anxiety, panic attacks, restlessness, insomnia, hostility, impulsivity, aggression, somnolence restlessness (akathisia), mania. When the patient has these symptoms, the lowest dose may be considered to reduce the risk of overdose.
Risk of fracture Statistics have shown that the risk of fracture tends to increase in patients taking serotonin reuptake inhibitors, including Venlafaxin. To date, the cause of this condition has not been elucidated.
Closed-angle glaucoma When using Venlafaxin can appear pupil dilation. Patients with a history of glaucoma or at risk of acute angle-closure glaucoma should be closely monitored.
Cardiovascular disease Patients with a history of myocardial infarction or unstable heart disease should be used with caution
Venlafaxine has not been evaluated in patients with a recent history of myocardial infarction or cardiac disease. unstable heart. Therefore, caution should be exercised when administering Venlafaxin to these patients.
Convulsions Patients with a history of convulsions should be used with caution because of the potential for seizures during treatment with Venlafaxine.
Excited states Excited states may occur in a small number of patients with psychosis when taking antidepressants, including Venlafaxine. Therefore, caution should be exercised when using the drug in patients with a personal or family history of bipolar disorder.